Marksans Pharma peers

Companies like Marksans Pharmalatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,290 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MARKSANS
FY26
GRANULES
FY26
METROPOLIS
FY26
PARKHOSPS
FY26
Peer
Average
Valuation — at last close
P/E34.20×34.22×60.27×◆ 32.21×42.23× -19%
P/B4.73×◆ 4.08×7.59×4.73×5.47× -14%
EV/EBITDA22.24×◆ 17.84×28.22×21.24×22.43× -1%
Market Cap₹14,290 Cr₹20,750 Cr₹11,483 Cr₹9,556 Cr₹13,930 Cr +3%
Growth
Revenue CAGR 3Y◆ 16.80%5.95%12.75%—9.35% +80%
Revenue CAGR 5Y◆ 16.48%10.63%10.52%—10.57% +56%
Net Income CAGR 3Y◆ 16.55%4.82%10.06%—7.44% +122%
Revenue YoY (latest Q)◆ 35.61%22.04%16.62%—19.33% +84%
Net Income YoY (latest Q)◆ 173.89%59.77%25.72%—42.75% +307%
Profitability
EBITDA Margin20.36%22.09%24.36%◆ 26.46%24.30% -16%
Net Income Margin14.23%11.09%11.62%◆ 16.29%13.00% +9%
Return on Common Equity◆ 25.56%13.52%13.36%12.77%13.22% +93%
Return on Capital Employed◆ 27.82%18.00%15.82%16.72%16.85% +65%
Return on Assets◆ 20.08%8.52%9.55%9.72%9.26% +117%
Credit & Quality
Total Debt/Equity◆ 0.01×0.26×0.01×0.11×0.13× -92%
Interest Coverage◆ 20.81×7.77×10.88×6.48×8.38× +148%
Scale — latest FY
Revenue / Total Income₹2,951 Cr₹5,366 Cr₹1,646 Cr₹1,679 Cr₹2,897 Cr +2%
Net Income₹420 Cr₹595 Cr₹191 Cr₹274 Cr₹353 Cr +19%
Total Assets₹3,861 Cr₹7,720 Cr₹2,138 Cr₹2,813 Cr₹4,224 Cr -9%
EPS₹9.22₹24.47₹9.19₹6.87₹13.51 -32%
Book Value per Share₹66.71₹205.21₹72.98₹46.81₹108.33 -38%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.